Form 4 for DNTH Dianthus Therapeutics, Inc. /DE/

Accepted 2023-10-03 00:00:00 ET · period of report 2023-09-29 · accession 0001104659-23-106378 · SEC index · Original document

Summary rows

Aggregated the way they appear in lists: one row per insider, transaction code and security table.

X	Filed	Traded	Ticker	Insider	Title	Type	Price	Qty	Owned	ΔOwn	Value
I	2023-10-03	2023-09-29	DNTH	Harwin Peter Evan	Dir, 10%	P - Purchase	$13.63	+24.7K	1.93M	+1%	+$336.3K

Purchase Sale Sale after option exercise All abbreviations

#	Table	Security	Date	Code	A/D	Shares	Price	Owned after	Own	Exercise / expiry	Underlying	Footnotes
1	Common	Common Stock	2023-09-29	P	A	24,670	$13.63	1,928,503	I See footnote	—	—	(F1) Consists of 24,670 shares of common stock purchased by Fairmount Healthcare Fund II LP ("Fund II"). (F2) This transaction was executed in multiple trades at prices ranging from $13.45 to $13.645. The price reported above reflects the weighted average purchase price. The Reporting Persons hereby undertake to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. (F3) Consists of (i) 58,857 shares of common stock held of record by Fairmount Healthcare Fund LP ("Fund I"), (ii) 1,807,500 shares of common stock held of record by Fund II and (iii) 62,146 shares of common stock held of record by Fairmount SPV III, LLC. Fairmount Funds Management LLC ("Fairmount") is the investment manager for Fund I and Fund II and is the Class A Member for Fairmount SPV III, LLC. The general partner of Fairmount is Fairmount Funds Management GP LLC ("Fairmount GP"), of which Peter Harwin and Tomas Kiselak are the managing members. Fairmount, Fairmount GP, Mr. Harwin, and Mr. Kiselak disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein.